Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and ...
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial In the phase III ...
Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe. Oral gamma secretase inhibitor Ogsiveo ...
AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...
Visit a quote page and your recently viewed tickers will be displayed here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback